Thermo Fisher Scientific Inc. (TMO) is set to acquire Solventum's purification and filtration business for $4.1 billion, aiming to accelerate growth in biopharma manufacturing. This acquisition has been well received with significant positive impact on the Solventum stock. Thermo Fisher has also announced the launch of the CorEvitas registry dedicated to furthering lupus research and treatment, and has been seen as a high potential dividend stock by hedge funds. Thermo Fisher will be presenting at the upcoming TD Cowen 45th Annual Healthcare Conference and has been significantly expanding its board. The full year earnings for 2024 have outdone the predictions, which is driven largely by the introduction of new products. The company has also implemented a renewable electricity goal for its European operations and plans to accelerate this goal with a new solar power agreement with X-ELIO. An intensive SWOT analysis indicates favorable stock outlook amidst new acquisitions and growth in the Chinese market.
Thermo Fisher Scientific TMO News Analytics from Thu, 11 Jul 2024 07:00:00 GMT to Fri, 28 Feb 2025 21:55:34 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor 5
